Eyenovia Announces Closing of Public Offering

Core Viewpoint - Eyenovia, Inc. has successfully closed a public offering of 12,850,000 shares of common stock at a price of $0.40 per share, raising approximately $5.14 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering consisted of 12,850,000 shares priced at $0.40 each, resulting in gross proceeds of about $5.14 million [1][2]. - The net proceeds will be utilized for commercialization activities for Mydcombi and clobetasol propionate, completion of the CHAPERONE pediatric myopia clinical study, and general corporate purposes, including potential debt repayment [2]. Group 2: Placement Agent - Dawson James Securities, Inc. served as the placement agent for the offering [3]. Group 3: Regulatory Information - The securities were offered under a previously filed shelf registration statement on Form S-3, effective since December 23, 2021, with the offering conducted via a prospectus supplement [4].